GENEVA–(BUSINESS WIRE)–Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented updated long-term results from a Phase 1/1b study of NI-1801 as a monotherapy and in combination with pembrolizumab in heavily pretreated Platinum Resistant Ovarian Cancer (PROC) patients that have no approved standard of care treatment. The data were reported in a Poster presentation at European Society of Medical Oncolo